Found: 50
Select item for more details and to access through your institution.
Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1450, doi. 10.1111/bjh.19163
- By:
- Publication type:
- Article
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 6, p. 1103, doi. 10.1111/bjh.18772
- By:
- Publication type:
- Article
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 869, doi. 10.1111/bjh.16980
- By:
- Publication type:
- Article
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 319, doi. 10.1111/bjh.16059
- By:
- Publication type:
- Article
Multiple myeloma: patient outcomes in real-world practice.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 2, p. 252, doi. 10.1111/bjh.14213
- By:
- Publication type:
- Article
Multiple myeloma: practice patterns across Europe.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 1, p. 66, doi. 10.1111/bjh.14193
- By:
- Publication type:
- Article
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 5, p. 659, doi. 10.1111/bjh.12675
- By:
- Publication type:
- Article
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 264, doi. 10.1002/ajh.26785
- By:
- Publication type:
- Article
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.00704
- By:
- Publication type:
- Article
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 3, p. 290, doi. 10.1111/ejh.14225
- By:
- Publication type:
- Article
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
- Published in:
- PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0243309
- By:
- Publication type:
- Article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
- By:
- Publication type:
- Article
Continued survival gains in recent years among critically ill myeloma patients.
- Published in:
- Intensive Care Medicine, 2009, v. 35, n. 3, p. 512, doi. 10.1007/s00134-008-1320-4
- By:
- Publication type:
- Article
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
- By:
- Publication type:
- Article
Corrigendum to "OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT" [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 425, doi. 10.1016/j.clml.2022.03.010
- By:
- Publication type:
- Article
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02337-5
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
ICARIA-MM study: efficacy analysis according to prior lines of treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e245, doi. 10.1016/j.clml.2019.09.407
- By:
- Publication type:
- Article
MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e253, doi. 10.1016/j.clml.2019.09.419
- By:
- Publication type:
- Article
Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e225, doi. 10.1016/j.clml.2019.09.375
- By:
- Publication type:
- Article
Maintenance with Weekly Carfilzomib in Elderly newly Diagnosed Multiple Myeloma (IFM 2012-03).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e44, doi. 10.1016/j.clml.2019.09.066
- By:
- Publication type:
- Article
A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e41, doi. 10.1016/j.clml.2019.09.062
- By:
- Publication type:
- Article
A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e40, doi. 10.1016/j.clml.2019.09.061
- By:
- Publication type:
- Article
Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e16, doi. 10.1016/j.clml.2019.09.023
- By:
- Publication type:
- Article
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.004
- By:
- Publication type:
- Article
ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S326, doi. 10.1016/j.clml.2019.07.313
- By:
- Publication type:
- Article
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e7, doi. 10.1016/j.clml.2017.03.013
- By:
- Publication type:
- Article
B-Cell and T-Cell Phenotypes in CVID Patients Correlate with the Clinical Phenotype of the Disease.
- Published in:
- Journal of Clinical Immunology, 2010, v. 30, n. 5, p. 746, doi. 10.1007/s10875-010-9424-3
- By:
- Publication type:
- Article
Immunoglobulin Dosage and Switch from Intravenous to Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Hypogammaglobulinemia: Decreasing Dosage Does Not Alter Serum IgG Levels.
- Published in:
- Journal of Clinical Immunology, 2010, v. 30, n. 4, p. 602, doi. 10.1007/s10875-010-9417-2
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Genetically determined telomere length and multiple myeloma risk and outcome.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 4, p. 1, doi. 10.1038/s41408-021-00462-y
- By:
- Publication type:
- Article
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3297
- By:
- Publication type:
- Article
Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1324, doi. 10.1002/ajh.25951
- By:
- Publication type:
- Article
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 6, p. 635, doi. 10.1002/ajh.25459
- By:
- Publication type:
- Article
Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Recommandations 2024 de l'Intergroupe francophone du myélome sur la prise en charge des gammapathies monoclonales de signification indéterminée.
- Published in:
- Hematologie, 2024, v. 30, n. 1, p. 71, doi. 10.1684/hma.2024.1840
- By:
- Publication type:
- Article
Cellules T à récepteur antigénique chimérique autologues anti-BCMA : une efficacité incontestable, la question de la persistance des cellules au centre des discussions.
- Published in:
- Hematologie, 2021, v. 27, p. 5, doi. 10.1684/hma.2021.1637
- By:
- Publication type:
- Article
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01188-x
- By:
- Publication type:
- Article
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-020-01004-y
- By:
- Publication type:
- Article
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
- By:
- Publication type:
- Article
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 5, p. 2412, doi. 10.1007/s12325-023-02480-7
- By:
- Publication type:
- Article
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
- By:
- Publication type:
- Article
Évaluation des représentations relatives aux médicaments chez les patients atteints de myélome multiple.
- Published in:
- Therapeutic Patient Education / Éducation Thérapeutique du Patient, 2017, v. 9, n. 2, p. 1, doi. 10.1051/tpe/2017002
- By:
- Publication type:
- Article
Real life management of patients hospitalized with multiple myeloma in France.
- Published in:
- PLoS ONE, 2018, v. 13, n. 5, p. 1, doi. 10.1371/journal.pone.0196596
- By:
- Publication type:
- Article